A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

Adult acute lymphoblastic leukemia (ALL) includes Ph-positive (Phpos) ALL, Ph-negative (Phneg) B-cell precursor (BCP) ALL and T-ALL/lymphoblastic lymphoma (LL), accounting for approximately 25, 50 and 25% of all cases, respectively. In younger adults, the results associated with standard therapy have markedly improved in these 3 groups, due to chemotherapy intensification in the BCP and T groups and addition of TKIs in the Phpos group, respectively. This led to reevaluate the role of allogeneic hematopoietic stem cell transplantation (HSCT) in first remission, which is generally now indicated

Trial Details

NCT ID
NCT06860269
Phase
PHASE2 / PHASE3
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Randomization + Blinatumomab + chemotherapy
  • Randomization + Standard frontline T-ALL chemotherapy backbone
  • Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone
  • Randomization + Blinatumomab + Ponatinib + chemotherapy
  • Randomization 1 + Allo HSCT
  • Randomization 2 + Allo HSCT
Locations (sample)
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • Patients aged 18 to 65 years old
  • Newly diagnosed ALL or T-LL according to the WHO criteria
  • Immunophenotypic, cytogenetic and/or FISH and molecular evaluation performed and allowing classifying the patient in one of the Phpos ALL, Phneg BC…
  • Not previously treated except with corticosteroids and/or intrathecal therapy (prephase)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →